Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. antigen specific
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Antigen Specific Articles & Analysis

80 news found

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

CD Bioparticles Launches Advanced Bio-Targeted Small Molecules Conjugated Magnetic Nanoparticles for Targeted Cancer Therapy

Combined with nanotechnology, "smart" drugs can actively target tumors by binding to corresponding receptors on tumor cells through interactions with phenotype-specific ligands conjugated to the delivery vehicle. Additionally, binding to certain receptors can trigger internalization and help avoid the development of resistance mechanisms. ...

ByCD Bioparticles


CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

These sophisticated compounds elegantly bind monoclonal antibodies to cytotoxic agents via linkers, targeting specific antigens while minimizing systematic exposure. This technique combines the selectivity of antibodies with the potency of cytotoxic drugs, allowing for a highly focused approach to disease management, especially in oncology research. ...

ByCD Formulation


Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development

Creative Diagnostics Launches Comprehensive ELISA Based Assays for Vaccine Development

ELISA-based immunoassays are the gold standard for various aspects of vaccine bioanalysis, including quantification of antigenic epitopes, detection of contaminants, and determination of vaccine efficacy (e.g., vaccine titer and immunogenicity). ...

ByCreative Diagnostics


Bayer expands global clinical program for darolutamide in prostate cancer

Bayer expands global clinical program for darolutamide in prostate cancer

BCR is defined as rising prostate-specific antigen (PSA) levels with a doubling time of after primary treatment (surgery or radiotherapy).1,2 Darolutamide is already approved under the brand name NubeqaTM for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease as well ...

ByBayer AG


Nubeqa (darolutamide) approved for additional prostate cancer indication in China

Nubeqa (darolutamide) approved for additional prostate cancer indication in China

In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...

ByBayer AG


Nubeqa approved for additional indication in Japan

Nubeqa approved for additional indication in Japan

In addition, a study to explore the potential of darolutamide in the early setting for patients who have experienced a rise in their prostate specific antigen (PSA) levels following surgery or radiation, is also planned. ...

ByBayer AG


Big Data Meets Big Biology in San Diego: Some Takeaways

Big Data Meets Big Biology in San Diego: Some Takeaways

At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. ...

ByLynx Biosciences, Inc.


Engineering antibody-antigen interfaces to improve therapeutic properties

Engineering antibody-antigen interfaces to improve therapeutic properties

A case for antibody engineering B cells produce antibodies in response to the presence of antigens. These antibodies then recognize and bind to antigens, triggering one of several downstream activities, such as: Neutralization by alteration of the chemical composition of an antigen Immobilization of the antigen-presenting ...

ByCresset Group


Creative BioMart Provides MHC Solutions for Cell Therapy & Vaccine Development

Creative BioMart Provides MHC Solutions for Cell Therapy & Vaccine Development

According to the official speaker from Creative BioMart, based on MHC-like complexes that can directly identify and isolate antigen-specific T cells or screen and identify MHC-like antigens that can be used for vaccine development, the company can provide two therapeutic development services: cell therapy and vaccine development. ...

ByCreative BioMart


CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences

CTT to Present Data on Prostate Cancer Therapy Candidates at Upcoming Conferences

The company’s first candidate targets the prostate specific membrane antigen (PSMA) in prostate cancer, which is proposed to have both diagnostic and therapeutic applications. ...

ByCancer Targeted Technology


ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's medical radioisotope, non-carrier-added Lutetium-177 (n.c.a. 177Lu, EndolucinBeta®). ...

ByITM Isotope Technologies Munich SE


ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells

(USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells ...

ByRarecells Diagnostics SAS


I Lost One of the Most Vital Organs - Prostate Cancer Patient Stories

I Lost One of the Most Vital Organs - Prostate Cancer Patient Stories

Prostate cancer is the most common type of cancer in men. Every year this diagnosis is made about 900 thousand times, in developed countries the disease affects up to 14% of the entire male population with oncology due to longer life expectancy. We spoke with adult prostate cancer survivors. ...

ByProUroCare Medical Inc.


Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

Analysis supporting treatment with Diamyd published in peer-reviewed scientific journal

The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. ...

ByDiamyd Medical AB


Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

Immunological analysis of prevention trial with Diamyd published in peer-reviewed scientific journal

The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. ...

ByDiamyd Medical AB


All patients in DiagnodE-B have received an additional (booster) injection of Diamyd

All patients in DiagnodE-B have received an additional (booster) injection of Diamyd

The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. ...

ByDiamyd Medical AB


iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

Vaccines As previously reported, preclinical studies of IBIO-202, the Company’s vaccine candidate that uses a nucleocapsid (“N”) antigen rather than the more mutable spike (“S”) protein of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response. ...

ByIbio, Inc.


Updated results from clinical trial with Diamyd presented today at diabetes conference

Updated results from clinical trial with Diamyd presented today at diabetes conference

The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. ...

ByDiamyd Medical AB


AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate

AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate

The results were published in the article “A Personal COVID-19 Dendritic Cell Vaccine Made at Point-of-Care: Feasibility, Safety, and Antigen-Specific Cellular Immune Responses” in the journal Human Vaccines & Immunotherapeutics. ...

ByAIVITA Biomedical, Inc.


Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

Five-month results from Diamyd trial in LADA published in peer-reviewed scientific journal

As communicated on December 7, 2021, immunological analyses after 5-months showed that the treatment with Diamyd® induced a clear GAD-specific immune response both in term of antibodies and cell-based reactions in individuals diagnosed with LADA . ...

ByDiamyd Medical AB

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT